ISUPREL Drug Patent Profile

When do Isuprel patents expire, and what generic alternatives are available?

Isuprel is a drug marketed by Sanofi Aventis Us and Bausch and is included in four NDAs.

The generic ingredient in ISUPREL is isoproterenol hydrochloride. There is one drug master file entry for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the isoproterenol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Isuprel

A generic version of ISUPREL was approved as isoproterenol hydrochloride by NEXUS on August 2^nd, 2017.

Summary for ISUPREL

US Patents:	0
Applicants:	2
NDAs:	4
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	5
Patent Applications:	1,976
Drug Prices:	Drug price information for ISUPREL
What excipients (inactive ingredients) are in ISUPREL?	ISUPREL excipients list
DailyMed Link:	ISUPREL at DailyMed

See drug prices for ISUPREL

Recent Clinical Trials for ISUPREL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Brain & Behavior Research Foundation	N/A
University of Oklahoma	N/A
Vanderbilt University Medical Center	N/A

See all ISUPREL clinical trials

US Patents and Regulatory Information for ISUPREL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	ISUPREL	isoproterenol hydrochloride	AEROSOL, METERED;INHALATION	011178-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Sanofi Aventis Us	ISUPREL	isoproterenol hydrochloride	SOLUTION;INHALATION	006327-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Bausch	ISUPREL	isoproterenol hydrochloride	INJECTABLE;INJECTION	010515-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Isuprel Market Dynamics, Financial Trajectory, Patent Status, and Generic Entry Risk

Last updated: August 9, 2026

Isuprel, the branded injectable form of isoproterenol hydrochloride, is a mature hospital drug with limited patent protection, no biologic exclusivity, and long-established generic competition. Its commercial history has been driven less by innovation than by ownership changes, hospital supply conditions, price increases, and the clinical need for a rapidly acting beta-adrenergic agonist in specialized cardiovascular settings.

Standalone Isuprel revenue is not consistently disclosed by its commercial owners. Public filings generally aggregate Isuprel with other hospital and specialty products, preventing a reliable current revenue series. The product’s economic value has historically reflected high unit pricing and clinical scarcity rather than large prescription volume.

What is Isuprel and how is it used?

Isuprel contains isoproterenol hydrochloride, a nonselective beta-adrenergic agonist administered by injection. It increases heart rate and myocardial contractility and can produce peripheral vasodilation.

The FDA-approved product has been used in specialized acute-care settings, including:

• Bradycardia and certain forms of heart block
• Adams-Stokes attacks
• Cardiogenic or distributive shock in selected circumstances
• Bronchospasm in historical labeling
• Temporary cardiac stimulation during procedures or while awaiting definitive pacing

Contemporary use is concentrated in hospitals, operating rooms, intensive-care units, electrophysiology settings, and emergency cardiovascular care. Isoproterenol is also used in electrophysiology laboratories to provoke arrhythmias during ablation procedures, although product selection and labeling can vary by institution.

What is the active ingredient and dosage form?

Attribute	Isuprel profile
Active ingredient	Isoproterenol hydrochloride
Drug class	Nonselective beta-adrenergic agonist
Primary dosage form	Sterile injectable solution
Route	Intravenous infusion or other parenteral administration under medical supervision
Customer base	Hospitals, health systems, surgery centers, cardiac-care facilities
Primary commercial channel	Institutional purchasing and specialty distribution
Regulatory category	Small-molecule prescription drug
Biosimilar relevance	None

The injectable presentation creates manufacturing and supply-chain barriers that do not apply to ordinary oral generic drugs. Sterile filling, validated aseptic processes, quality-control testing, and hospital supply reliability are central commercial considerations.

How has the Isuprel market evolved?

Isuprel is a legacy product whose market has passed through three distinct commercial phases.

Legacy branded phase

Isoproterenol has been available for decades. Its core clinical uses were established before the modern patent and exclusivity framework became commercially important. The product therefore does not depend on a recent composition-of-matter patent or a novel FDA exclusivity period.

Price-expansion phase

Isuprel became associated with aggressive hospital-drug price increases after Valeant Pharmaceuticals acquired rights to the product and Nitropress. Congressional materials reported that the price of Isuprel increased substantially during Valeant’s ownership, with the price per vial rising from approximately $215 to more than $1,000 in 2015. The precise price depends on the product presentation, purchasing channel, and date used for comparison.[1]

The commercial strategy relied on the product’s:

• Low unit volume
• Hospital dependence
• Limited immediate substitutes in certain procedures
• High clinical switching costs
• Supply sensitivity in sterile injectable products

The price increases generated regulatory, political, and investor scrutiny. They also increased the product’s exposure to substitution by generic manufacturers and to institutional formulary review.

Mature and competitive phase

Isuprel now operates in a market where the underlying active ingredient is old and generic alternatives exist or have existed. Brand economics depend on whether hospitals require the branded product, whether generic supply is stable, and whether the purchaser receives a material price discount from generic suppliers.

The most important commercial risks are therefore operational rather than patent-based:

• Generic availability
• FDA shortage conditions
• Manufacturing interruptions
• Hospital contracting
• Wholesaler inventory
• Product-specific clinical familiarity
• The ability to maintain sterile injectable quality

What is the financial trajectory of Isuprel?

The financial trajectory is best understood as a price-and-volume story rather than a conventional innovation-product growth story.

Period	Market dynamic	Financial effect
Before 2015	Mature hospital injectable with established clinical use	Stable, limited-volume economics
2015	Significant branded price increases reported during Valeant ownership	Sharp increase in potential revenue per vial
2016 onward	Public and payer scrutiny, generic competition, and hospital purchasing pressure	Greater risk of volume erosion and price normalization
Recent market	Mature product with institutional demand and supply sensitivity	Revenue depends on availability, contracting, and product continuity

Standalone annual sales figures should not be inferred from parent-company segment revenue. Valeant and other owners reported broad business segments that included multiple hospital products. Without a product-level disclosure, reported segment growth cannot be assigned to Isuprel.

Why can a low-volume drug generate substantial revenue?

A hospital injectable can produce meaningful revenue without a large prescription base when:

1. The drug is used in high-acuity procedures.
2. Hospitals maintain inventory because substitution is difficult during emergencies.
3. The product has limited competitors at a particular time.
4. Unit prices increase faster than utilization declines.
5. Purchasers value supply continuity over lowest acquisition cost.

This model is vulnerable. Once a generic supplier establishes reliable supply, hospitals can shift purchasing rapidly, particularly when the clinical distinction between brand and generic is limited.

What is the revenue exposure for the commercial owner?

Isuprel’s revenue exposure is concentrated in institutional purchasing rather than retail pharmacy demand. Key revenue drivers include:

• Number of electrophysiology and cardiac procedures
• Hospital stocking policies
• Generic tender outcomes
• Contracted acquisition price
• Shortage conditions
• Product discontinuation or manufacturing interruptions
• Reimbursement and hospital budget pressure

The product has no meaningful direct-to-consumer revenue engine. Its financial performance is tied to procurement contracts and clinical availability.

What patents protect Isuprel?

The original active-ingredient and product patents for isoproterenol are long expired. Isuprel does not have the patent profile of a recently launched specialty drug.

Patent protection

Protection type	Isuprel status
Composition-of-matter patent	Expired or commercially irrelevant due to the age of isoproterenol
New chemical entity exclusivity	Expired
Pediatric exclusivity	No material current relevance
Orphan-drug exclusivity	No current protection identified for the legacy product
Formulation patent	No known commercially significant active formulation barrier
Method-of-use patent	No known active method-of-use estate that blocks ordinary generic injectable use
Biosimilar exclusivity	Not applicable
Orange Book patent barrier	No material current patent barrier expected for the legacy injectable

The absence of a significant active patent estate means the branded product cannot rely on patent litigation to preserve market share. Any commercial protection comes from manufacturing capability, customer relationships, supply reliability, regulatory history, and institutional preference.

What is the Orange Book status of Isuprel?

The Orange Book is relevant because Isuprel is an FDA-approved small-molecule drug. It is not a biologic and does not rely on the Biologics Price Competition and Innovation Act pathway.

The commercial implications are straightforward:

• Generic applicants may use an abbreviated new drug application pathway.
• A generic applicant does not need to repeat the full clinical development program.
• Paragraph IV litigation is unlikely to create a meaningful barrier where no relevant unexpired patent is listed.
• Any residual exclusivity would depend on an FDA-recognized regulatory period, not the age of the brand name.

The FDA’s Drugs@FDA and Orange Book databases should be treated as the controlling sources for current application status, listed patents, and approved generic products.[2][3]

When did Isuprel lose exclusivity?

Isuprel lost meaningful market exclusivity long ago because isoproterenol is an established small-molecule active ingredient with a legacy approval history.

There is no current commercial exclusivity comparable to:

• Five-year new chemical entity exclusivity
• Three-year new clinical investigation exclusivity
• Seven-year orphan-drug exclusivity
• Twelve-year reference-product exclusivity for biologics

The relevant question is therefore not when Isuprel’s patent expires. It is whether approved generic manufacturers can supply the product consistently and whether hospitals accept substitution.

Are there Paragraph IV challenges to Isuprel?

Paragraph IV litigation is not the primary competitive risk for Isuprel. Paragraph IV certifications concern unexpired patents listed for an approved reference drug. A mature injectable with no material active patent listing does not present the same litigation profile as a patented tablet, extended-release product, or branded biologic.

Generic competition can proceed through ordinary ANDA approval where the applicant does not face a meaningful unexpired patent barrier. The commercial dispute, if any, is more likely to involve:

• FDA approval timing
• Product-specific manufacturing deficiencies
• Supply interruptions
• Contracting practices
• Shortage allocation
• Trade-name or trademark issues

What formulations are protected by Isuprel patents?

No commercially meaningful formulation moat is apparent for the conventional isoproterenol hydrochloride injection.

Potential technical barriers relate to manufacturing rather than patent exclusivity:

• Sterile injectable formulation
• Container-closure integrity
• Stability during storage
• Low-dose concentration accuracy
• Aseptic filling
• Particulate and sterility controls
• Validation of manufacturing processes
• Compatibility with infusion systems

These factors can delay or constrain generic entry even when patents do not. They do not, however, create the same durable market protection as a valid composition or formulation patent.

Which companies compete with Isuprel?

Competition comes from both direct generic isoproterenol products and clinical substitutes.

Direct product competition

Generic isoproterenol hydrochloride injection is the closest substitute. The supplier landscape can change because sterile injectables are frequently affected by plant inspections, contract-manufacturing constraints, component shortages, and discontinuations.

Clinical alternatives

Depending on the indication, hospitals may use:

• Temporary transcutaneous or transvenous pacing
• Epinephrine
• Dopamine
• Dobutamine
• Atropine
• Other vasoactive or chronotropic agents

These products are not pharmacologic equivalents in every setting. Their competitive effect depends on the clinical use case. In electrophysiology, isoproterenol may be preferred for its ability to increase adrenergic stimulation during procedural testing. In severe bradycardia, pacing may replace pharmacologic stimulation when clinically appropriate.

How strong is the Isuprel patent estate?

The patent estate is weak from a pharmaceutical exclusivity perspective.

Factor	Assessment
Patent duration	Fully mature
Active composition protection	None of material commercial value
Formulation protection	No material barrier identified
Method-of-use protection	No meaningful blocking estate identified
Generic substitution risk	High
Manufacturing barrier	Moderate
Supply-chain sensitivity	High
Brand pricing power	Limited outside shortage or continuity events
Litigation leverage	Low

Isuprel’s remaining defensibility is operational. A manufacturer with dependable sterile production, strong hospital contracts, and a reliable shortage record can retain business even without patent protection.

What generic entry risks exist for Isuprel?

Generic entry risk is structurally high, but the timing and impact of entry depend on supply conditions.

Base-case generic scenario

The most likely long-term scenario is continued generic availability with brand demand limited to:

• Hospitals with established brand contracts
• Facilities concerned about supply continuity
• Physicians or pharmacists with product-specific preferences
• Periods of generic shortage
• Accounts receiving favorable branded pricing

Downside scenario for the brand

Brand revenue can decline rapidly if:

• Multiple generic suppliers achieve reliable supply
• Hospital systems standardize on generic isoproterenol
• Contract prices fall
• The brand loses preferred wholesaler status
• FDA or payer scrutiny intensifies
• The manufacturer experiences a supply interruption

Temporary upside scenario

Shortages or manufacturing disruptions can temporarily increase branded demand and pricing power. This upside is difficult to sustain because it attracts additional suppliers and encourages hospital substitution once supply normalizes.

What FDA regulatory issues affect Isuprel?

The principal FDA issues are product quality, manufacturing compliance, labeling, and supply continuity.

For sterile injectables, FDA scrutiny commonly focuses on:

• Current good manufacturing practice compliance
• Sterility assurance
• Environmental monitoring
• Container-closure systems
• Visible and subvisible particles
• Stability data
• Batch release controls
• Manufacturing-site inspection history

FDA shortage information is commercially important. A shortage can increase demand for the brand or another supplier, but it can also expose dependence on a single manufacturing site.[4]

The product’s regulatory risk is therefore more closely tied to continued approval and supply reliability than to clinical development.

What patent litigation affects Isuprel?

No major current patent litigation is central to the Isuprel market. The legacy product lacks the patent estate that typically generates Hatch-Waxman litigation over generic entry.

Historical controversy centered on pricing and commercial conduct rather than patent validity. Valeant’s price increases for Isuprel and Nitropress received congressional scrutiny and became part of broader discussions about hospital-drug pricing, specialty pharmaceuticals, and acquisition-driven price increases.[1]

Are licensing deals important to Isuprel?

Licensing and asset-transfer arrangements have been important because Isuprel has changed commercial ownership during its mature-product life cycle. Those transactions affected pricing strategy, portfolio classification, and distribution, but they did not create new patent exclusivity.

For an acquirer, the material diligence questions are:

• Which entity owns the NDA or has commercialization rights?
• Who controls manufacturing?
• Are supply agreements transferable?
• Are there authorized generic rights?
• What hospital contracts are assignable?
• Are there outstanding quality commitments?
• Does the transaction include related products such as Nitropress or other hospital injectables?

Ownership changes can alter revenue recognition and pricing without changing the product’s underlying medical demand.

How does Isuprel compare with newer cardiovascular drugs?

Isuprel differs from newer cardiovascular products in four ways.

Dimension	Isuprel	Newer cardiovascular drugs
Patent position	Legacy and largely unprotected	Often protected by composition and formulation patents
Demand	Hospital, episodic, procedure-driven	May be chronic, outpatient, or specialty
Revenue model	Institutional procurement	Retail, specialty pharmacy, or hospital mix
Main risk	Supply and generic substitution	Patent expiry, clinical competition, and reimbursement

Isuprel can have high strategic value during a shortage despite low baseline volume. Newer drugs generally have more predictable demand but face larger patent cliffs and more extensive clinical competition.

Key Takeaways

• Isuprel is a mature isoproterenol hydrochloride injectable used mainly in specialized hospital and cardiovascular settings.
• Its original patent and regulatory exclusivity have expired.
• No material active formulation or method-of-use patent barrier is central to the current market.
• Generic substitution is the primary long-term commercial risk.
• Sterile-manufacturing capability and supply continuity provide more protection than intellectual property.
• The product’s 2015 financial trajectory was shaped by substantial price increases reported during Valeant ownership.
• Standalone current revenue is not reliably disclosed in public company filings.
• Hospital procurement, shortage conditions, and generic availability drive financial performance.
• Paragraph IV litigation and biosimilar competition are not material features of the market.
• Brand value is highest when generic supply is constrained or hospitals prioritize continuity over price.

Frequently Asked Questions

Is Isuprel still commercially available?

Isoproterenol injection remains an FDA-regulated hospital product, but availability can vary by manufacturer, presentation, and shortage conditions. Current status depends on FDA approval and supply records.

Is isoproterenol the same drug as Isuprel?

Isoproterenol is the active ingredient in Isuprel. Generic isoproterenol hydrochloride injection is the principal direct substitute for the branded product.

Can a generic manufacturer enter the Isuprel market without a patent lawsuit?

Yes. Where no relevant unexpired Orange Book patent blocks approval, a generic applicant can pursue an ANDA without relying on a contested Paragraph IV pathway.

Why can Isuprel maintain value after patent expiration?

Its value comes from hospital demand, procedural use, sterile-injectable manufacturing requirements, supply reliability, and the clinical cost of being out of stock.

Does Isuprel face biosimilar competition?

No. Isuprel is a chemically synthesized small-molecule drug, not a biologic. Its relevant competition comes from generic injectables and clinical alternatives.

References

1. United States Senate, Committee on Health, Education, Labor, and Pensions. (2016). Suddenly a $2.5 billion price hike: How Valeant Pharmaceuticals game the system. U.S. Senate.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (n.d.). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages